Pantoprazole and cyclosporine or tacrolimus.
Schwrer
H
H
Lorf
T
T
Ringe
B
B
Ramadori
G
G
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000378:metabolism / Q000494:pharmacology*; D001562:Benzimidazoles / Q000378:metabolism / Q000494:pharmacology*; D016572:Cyclosporine / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000494:pharmacology*; D008099:Liver; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000378:metabolism / Q000494:pharmacology*; D016559:Tacrolimus / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D007166:Immunosuppressive Agents; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D016572:Cyclosporine; D003577:Cytochrome P-450 Enzyme System; D000077402:Pantoprazole; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D009853:Omeprazole; D016559:Tacrolimus